In cell lines derived from patients with cancer, DMD, and CF, treatment with 25 μM of amlexanox stabilized PTC-containing mRNA and, in some cases, led to the production of full-length proteins such as dystrophin, p53, and CFTR [79]. This evidence concerns the gene TP53 and cancer.